Evidence for Two Modes of Synergistic Induction of Apoptosis by Mapatumumab and Oxaliplatin in Combination with Hyperthermia in Human Colon Cancer Cells

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Song, Xinxin ^a   Kim, Seog Young ^a   Lee, Yong J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 4; FLICE INHIBITORY PROTEIN; LIPOCORTIN 5; LYSINE; MAPATUMUMAB; OXALIPLATIN; PROTEIN BCL XL; PROTEIN C JUN; SERINE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER MORTALITY; COLON CANCER; DOWN REGULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; HYPERTHERMIA; IMMUNOPRECIPITATION; LIVER PERFUSION; MOLECULAR MECHANICS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TREATMENT OUTCOME; UBIQUITINATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SYNERGISM; HUMANS; HYPERTHERMIA, INDUCED; MITOCHONDRIA; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 84883163991     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073654     Document Type: Article

References (49)

1. Ruers T, Bleichrodt RP, (2002) Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 38: 1023-1033. doi:10.1016/S0959-8049(02)00059-X. PubMed: 11978527.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
3. Zeh HJ 3rd, Brown CK, Holtzman MP, Egorin MJ, Holleran JL, et al. (2009) A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol 16: 385-394. doi:10.1245/s10434-008-0179-5. PubMed: 19034580.
4. Alexander HR Jr., Libutti SK, Pingpank JF, Bartlett DL, Helsabeck C, et al. (2005) Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 12: 138-144. doi:10.1245/ASO.2005.05.003. PubMed: 15827794.
5. Varghese S, Xu H, Bartlett D, Hughes M, Pingpank JF, et al. (2010) Isolated hepatic perfusion with high-dose melphalan results in immediate alterations in tumor gene expression in patients with metastatic ocular melanoma. Ann Surg Oncol 17: 1870-1877. doi:10.1245/s10434-010-0998-z. PubMed: 20221901.
6. Hafström LR, Holmberg SB, Naredi PL, Lindnér PG, Bengtsson A, et al. (1994) Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol 3: 103-108. doi:10.1016/0960-7404(94)90005-1. PubMed: 7952389.
7. Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, et al. (2009) Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin Cancer Res 15: 5584-5590. doi:10.1158/1078-0432.CCR-09-0996. PubMed: 19690193.
8. Younes A, Vose JM, Zelenetz AD, Smith MR, Burris HA, et al. (2010) A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 103: 1783-1787. doi:10.1038/sj.bjc.6605987. PubMed: 21081929.
9. Vulfovich M, Saba N, (2005) Technology evaluation: mapatumumab, Human Genome Sciences/GlaxoSmithKline/Takeda. Curr Opin Mol Ther 7: 502-510. PubMed: 16248286.
10. Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M, et al. (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 102: 506-512. doi:10.1038/sj.bjc.6605507. PubMed: 20068564.
11. Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, et al. (2008) Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61: 82-90. doi:10.1016/j.lungcan.2007.12.011. PubMed: 18255187.
12. Zhang L, Fang B, (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237. doi:10.1038/sj.cgt.7700792. PubMed: 15550937.
13. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, et al. (2013) On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 32: 1341-1350. doi:10.1038/onc.2012.164. PubMed: 22580613.
14. Mahalingam D, Oldenhuis CN, Szegezdi E, Giles FJ, de Vries EG, et al. (2011) Targeting TRAIL towards the clinic. Curr Drug Targets 12: 2079-2090. doi:10.2174/138945011798829357. PubMed: 21777191.
15. Hegewisch-Becker S, Gruber Y, Corovic A, Pichlmeier U, Atanackovic D, et al. (2002) Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Ann Oncol 13: 1197-1204. doi:10.1093/annonc/mdf216. PubMed: 12181242.
16. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E, (2002) Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 1: 227-235. PubMed: 12467217.
17. El Fajoui Z, Toscano F, Jacquemin G, Abello J, Scoazec JY, et al. (2011) Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. Gastroenterology 141: 663-673. doi:10.1053/j.gastro.2011.04.055. PubMed: 21683075.
18. Atallah D, Marsaud V, Radanyi C, Kornprobst M, Rouzier R, et al. (2004) Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. Int J Hyperthermia 20: 405-419. doi:10.1080/02656730310001637325. PubMed: 15204521.
19. Song X, Kim SY, Lee YJ, (2012) The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer. Mol Cancer Res 10: 1567-1579. doi:10.1158/1541-7786.MCR-12-0209-T. PubMed: 23051936.
20. Libutti SK, Barlett DL, Fraker DL, Alexander HR, (2000) Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg 191: 519-530. doi:10.1016/S1072-7515(00)00733-X. PubMed: 11085732.
21. Lee YJ, Galoforo SS, Battle P, Lee H, Corry PM, et al. (2001) Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. Cancer Gene Ther 8: 397-404. doi:10.1038/sj.cgt.7700310. PubMed: 11498759.
22. Cummins JM, Kohli M, Rago C, Kinzler KW, Vogelstein B, et al. (2004) X-linked inhibitor of apoptosis protein (XIAP) is a nonredundant modulator of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in human cancer cells. Cancer Res 64: 3006-3008. doi:10.1158/0008-5472.CAN-04-0046. PubMed: 15126334.
23. Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz DB, et al. (2008) A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer Res 68: 6932-6941. doi:10.1158/0008-5472.CAN-07-5779. PubMed: 18757407.
24. Gao W, Chen L, Ma Z, Du Z, Zhao Z, et al. (2013) Isolation and Phenotypic Characterization of Colorectal Cancer Stem Cells with Organ-Specific Metastatic Potential. Gastroenterology. PubMed: 23747337.
25. Liu C, Xue H, Lu Y, Chi B, (2012) Stem cell gene Girdin: a potential early liver metastasis predictor of colorectal cancer. Mol Biol Rep 39: 8717-8722. doi:10.1007/s11033-012-1731-8. PubMed: 22714912.
26. Zhao L, Yue P, Lonial S, Khuri FR, Sun SY, (2011) The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. Mol Cancer Ther 10: 2415-2425. doi:10.1158/1535-7163.MCT-11-0401. PubMed: 21914854.
27. Lin Y, Liu X, Yue P, Benbrook DM, Berlin KD, et al. (2008) Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther 7: 3556-3565. doi:10.1158/1535-7163.MCT-08-0648. PubMed: 19001438.
28. Song X, Kim SY, Zhou Z, Lagasse E, Kwon YT, et al. (2013) Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells. Cell Death Dis 4: e577. doi:10.1038/cddis.2013.104. PubMed: 23559011.
29. Song X, Kim HC, Kim SY, Basse P, Park BH, et al. (2012) Hyperthermia-enhanced TRAIL- and mapatumumab-induced apoptotic death is mediated through mitochondria in human colon cancer cells. J Cell Biochem 113: 1547-1558. PubMed: 22174016.
30. Alcala MA Jr., Park K, Yoo J, Lee DH, Park BH, et al. (2010) Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors. J Cell Biochem 110: 1073-1081. doi:10.1002/jcb.22619. PubMed: 20544795.
31. Yoo J, Lee YJ, (2008) Effect of hyperthermia and chemotherapeutic agents on TRAIL-induced cell death in human colon cancer cells. J Cell Biochem 103: 98-109. doi:10.1002/jcb.21389. PubMed: 17520700.
32. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, et al. (2012) Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149: 780-794. doi:10.1016/j.cell.2012.03.031. PubMed: 22579283.
33. Jin-Song Y, Zhao-Xia W, Cheng-Yu L, Xiao-Di L, Ming S, et al. (2011) Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem 113: 810-814. doi:10.1016/j.acthis.2011.01.002. PubMed: 21277008.
34. Upreti M, Galitovskaya EN, Chu R, Tackett AJ, Terrano DT, et al. (2008) Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J Biol Chem 283: 35517-35525. doi:10.1074/jbc.M805019200. PubMed: 18974096.
35. Ubersax JA, Ferrell JE Jr., (2007) Mechanisms of specificity in protein phosphorylation. Nat Rev Mol Cell Biol 8: 530-541. doi:10.1038/nrm2203. PubMed: 17585314.
36. Krueger A, Baumann S, Krammer PH, Kirchhoff S, (2001) FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21: 8247-8254. doi:10.1128/MCB.21.24.8247-8254.2001. PubMed: 11713262.
37. Lavrik IN, Krammer PH, (2012) Regulation of CD95/Fas signaling at the DISC. Cell Death Differ 19: 36-41. doi:10.1038/cdd.2011.155. PubMed: 22075988.
38. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S, (2001) Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276: 20633-20640. doi:10.1074/jbc.M101780200. PubMed: 11279218.
39. Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, et al. (2006) c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25: 838-848. doi:10.1038/sj.onc.1209122. PubMed: 16247474.
40. Yu JW, Shi Y, (2008) FLIP and the death effector domain family. Oncogene 27: 6216-6227. doi:10.1038/onc.2008.299. PubMed: 18931689.
41. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, et al. (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195. doi:10.1038/40657. PubMed: 9217161.
42. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, et al. (2007) c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 67: 5754-5762. doi:10.1158/0008-5472.CAN-06-3585. PubMed: 17575142.
43. Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, et al. (2007) Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 13: 5070-5075. doi:10.1158/1078-0432.CCR-06-2547. PubMed: 17785559.
44. Mawji IA, Simpson CD, Gronda M, Williams MA, Hurren R, et al. (2007) A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res 67: 8307-8315. doi:10.1158/0008-5472.CAN-07-1687. PubMed: 17804746.
45. Seo BR, Min KJ, Kim S, Park JW, Park WK, et al. (2013) Anisomycin treatment enhances TRAIL-mediated apoptosis in renal carcinoma cells through the down-regulation of Bcl-2, c-FLIP(L) and Mcl-1. Biochimie 95: 858-865. doi:10.1016/j.biochi.2012.12.002. PubMed: 23261849.
46. Bartke T, Siegmund D, Peters N, Reichwein M, Henkler F, et al. (2001) p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. Oncogene 20: 571-580. doi:10.1038/sj.onc.1204124. PubMed: 11313989.
47. Safa AR, Day TW, Wu CH, (2008) Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets 8: 37-46. doi:10.2174/156800908783497087. PubMed: 18288942.
48. Zhang YL, Pang LQ, Wu Y, Wang XY, Wang CQ, et al. (2008) Significance of Bcl-xL in human colon carcinoma. World J Gastroenterol 14: 3069-3073. doi:10.3748/wjg.14.3069. PubMed: 18494061.
49. Korkolopoulou P, Saetta AA, Levidou G, Gigelou F, Lazaris A, et al. (2007) c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Histopathology 51: 150-156. doi:10.1111/j.1365-2559.2007.02723.x. PubMed: 17559541.